Milestone: research institute shares patents and know-how globally through C-TAP

Wemos is delighted that the Spanish National Research Council (CSIC) shares its intellectual property and know-how for the production of its Covid-19 diagnostic tool with the Covid-19 Technology Access Pool (C-TAP) of the World Health Organization (WHO). As such, CSIC permits all qualified manufacturers worldwide to make the product and distribute it to any country in the world, royalty-free for low- and middle-income countries. This is the first global, non-exclusive license for a Covid-19 innovation and thus a milestone for equal access to medical products.

Global access

Wemos is a strong advocate of the use of C-TAP. In May 2020, WHO established this platform to enhance equitable global access to essential commodities to fight Covid-19 as soon and effective as possible.

Through C-TAP, manufacturers of innovations for the prevention and control of Covid-19 can share their intellectual property rights and know-how, optionally in return for a fee. Consequently, all certified manufacturers worldwide may produce these commodities too and distribute them for affordable prices to low- and middle-income countries. The Medicines Patent Pool (MPP) assists C-TAP in negotiations with manufacturers.

Following the example

CSIC is now, 18 months after the creation of C-TAP, the first to contribute to the platform. CSIC is a public research institution associated with the Spanish government. So far, pharmaceutical companies have refrained from sharing their intellectual property rights and know-how through C-TAP, which has in particular resulted in major vaccine shortages in many countries.

The example of CSIC shows that C-TAP is now an operational mechanism to make medical products against Covid-19 widely available. Wemos calls upon pharmaceutical companies to follow suit and urges national governments to actively support C-TAP and stimulate companies to share their information too.


Recently, pharmaceutical companies Merck and Pfizer announced that they are sharing their intellectual property and know-how for their antivirals against Covid-19 with the MPP. A major difference with C-TAP is that Merck’s and Pfizer’s deals with the MPP are limited to access to a number of certain low- and middle-income countries. As a result, some middle-income countries, especially in South America and Asia, are excluded. The agreement between CSIC and C-TAP is non-exclusive and therefore does not exclude any country.

Through C-TAP, CSIC shares all intellectual property rights and know-how relevant for the production of its Covid-19 technology and it will provide training to potential manufacturers.

More information in this press release by WHO:

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent News items

Our highlights of 2021: seizing momentum for global health


We want everyone, everywhere to receive the health care services they need without suffering financial hardship. The path to achieving that goal is far from paved. However, in 2021 we have seen – and taken – opportunities to push for the structural changes that we envision. We are proud to present our highlights of 2021! 

Continue reading

New coalition agreement: this is what a Dutch Global Health Strategy should look like


The Covid-19 pandemic has strengthened calls for the need for a coherent Dutch Global Health Strategy. Wemos – as one of the founding members of the Dutch Global Health Alliance (DGHA) – is therefore thrilled to see that the Dutch government has included the intention to develop such a Strategy in the new coalition agreement ‘Omzien naar elkaar, vooruitkijken naar de toekomst’. As the Dutch Global Health Alliance, we have a clear position on the topic. Earlier this month, we shared our views in a policy brief that we submitted to the Advisory Council on International Affairs (AIV).

Continue reading